Howard A. Liebman, MD, USC

Articles

Future Directions in the Management of Immune Thrombocytopenia

September 1st 2022

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.

Other Novel Therapeutic Agents in Immune Thrombocytopenia

August 25th 2022

Before closing out their discussion on novel treatment approaches in ITP, experts review data behind FcR-, BTK-, and CD38-targeted therapies.

Novel Treatment Strategies in Immune Thrombocytopenia: Complement Inhibitors

August 25th 2022

Panelists review data behind sutimlimab, a complement inhibitor being investigated in the setting of immune thrombocytopenia.

Novel Treatment Strategies in Immune Thrombocytopenia: Frontline Use of TPO-RAs

August 18th 2022

Shared insight on clinical trials investigating the frontline use of thrombopoietin receptor agonists in patients with immune thrombocytopenia.

Treating Patients With Immune Thrombocytopenia in the Era of COVID-19

August 18th 2022

A brief review of how the management of patients with immune thrombocytopenia has been impacted by the COVID-19 pandemic.

How Does Treatment Duration Impact Outcomes in ITP?

August 11th 2022

Experts consider how treatment duration can impact patient outcomes in immune thrombocytopenia and discuss discontinuation of TPO-Ras.

Risk of Thrombosis With TPO-RAs in Immune Thrombocytopenia

August 11th 2022

Comprehensive discussion on nuancing the risk of thrombosis with thrombopoietin receptor agonists in immune thrombocytopenia.

Use of Romiplostim in Chronic Immune Thrombocytopenia

August 4th 2022

Considerations for the uptake and use of romiplostim, an injectable thrombopoietin receptor agonist, in immune thrombocytopenia.

Data on Avatrombopag in Chronic ITP

August 4th 2022

A commentary on clinical experience with avatrombopag, another oral TPO-RA, in treating ITP.

Eltrombopag in Chronic Immune Thrombocytopenia

July 28th 2022

Expert panelists consider clinical trial data on and personal experience with using eltrombopag, an oral TPO-RA, in immune thrombocytopenia.

Selecting an Oral TPO-RA for Chronic Immune Thrombocytopenia

July 28th 2022

A brief discussion of factors that influence selection of oral versus injectable TPO-RA therapy for ITP.

Thrombopoietin Receptor Agonists in Pediatric Immune Thrombocytopenia

July 21st 2022

Shared insight on thrombopoietin receptor agonist (TPO-RA) use in the pediatric setting of immune thrombocytopenia management.

Chronic Immune Thrombocytopenia: Considerations for Fostamatinib Therapy

July 21st 2022

Expert perspectives on the selection and use of fostamatinib as second-line therapy in patients with immune thrombocytopenia.

Use of Rituximab Therapy in Chronic Immune Thrombocytopenia

July 14th 2022

Focusing on second-line systemic agents in immune thrombocytopenia, experts review the historical use of rituximab therapy.

What is the Role of Splenectomy in Chronic Immune Thrombocytopenia?

July 14th 2022

Panelists consider when they would select splenectomy over second-line systemic therapy in patients with immune thrombocytopenia.

Defining Chronic or Persistent Immune Thrombocytopenia

July 7th 2022

Expert perspectives on how to identify chronic or persistent disease in patients diagnosed with immune thrombocytopenia.

The Significance of Patient Age in Treatment and Management of ITP

July 7th 2022

A commentary on the significance of the patient’s age in treating and managing ITP.

Optimizing Frontline Therapy in ITP: Treatment Selection and Goals

June 30th 2022

Shared insight on treatment goals for immune thrombocytopenia and how physicians might optimally select frontline therapy.

Making a Diagnosis of Immune Thrombocytopenia

June 30th 2022

Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.